We are
De Motu Cordis
Our Mission
To deliver life-saving medicine faster when every second counts
OUR PURPOSE
We relentlessly seek new technologies that will save lives and improve outcomes for patients facing life-threatening emergencies
OUR STORY
DMC is a clinical stage medtech company.
Founded in Queensland, Australia by Professor John Fraser AO, an intensivist, groundbreaking researcher and company founder, DMC develops emergency solutions for the immediate treatment of life-threatening conditions such as anaphylaxis. Their first-generation device aims to treat anaphylaxis by delivering epinephrine through inhalation, using the pulmonary pathway to deliver life-saving medication.
INVESTORS
DMC is planning a forthcoming capital raise in H2 2026, with preliminary discussions underway with potential investors. Please contact us via email.
DMC has a range of high net worth individual and family offices who have invested in our journey. If you would like to join them, please submit your details below.
Corporate Achievement
- Hire team
- Appoint governing board
- Secured BDF funding and R&D Tax Incentives
- Open new office premises
- Established QMS and cyber resilience
- Seed capital, expanded facilities
- Selected for BEDA Global Medtech Accelerator program
- Presented DMC progress at RESI conference, JP Morgan week, San Francisco
Product Development
- Texas Medical Centre Accelerator Program
- California Life Sciences Institute FAST Program, TIQ sponsorship
- Successful API particle engineering
- US Patent granted
- Formulation developed for rapid Tmax via the lung
- GMP manufacture for Phase 1
- Completion of testing for non-clinical program
- Successful first human clinical study
- Completion of Institutional Review Board (IRB) approved quantitative market research
- EU patent granted
- Pre-IND/FDA engagement
- US based commercial CDMO onboarded
- DMC-IH1 in vitro DPI device performance exceeds industry benchmark
- Completed formative Human Factors (HF) study